Two Diabetes Drugs Do Not Appear to Increase CV Risk in Type 2 Diabetes
Two studies presented at the ADA 75th Scientific Sessions assessed the cardiovascular safety of the diabetes drugs lixisenatide and sitagliptin in patients with type 2 diabetes. Findings indicated that neither drug did not increase CV risk in this patient population.
In the highly anticipated ELIXA study, he glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide appears to have a neutral effect on heart failure and other cardiovascular (CV) outcomes.
Likewise, data from the TECOS trial showed that the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin did not appear to increase the risk for CV events or hospitalization for heart failure in patients with type 2 diabetes and established heart disease.
Udayakabadi commented on August 13, 2015
Unfortunately, cardiovascular safety is looked at as no increase in CV outcomes despite lowering of A1c. We have forgotten that UKPDS,the ' Gold Standard ' longest duration study has shown that intensive therapy with SUs actually lowered CV outcomes by 16 %.